Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile
…, C Carcasona, B Reyes, D Vilella, J Gras… - … of Pharmacology and …, 2009 - ASPET
Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in
development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed …
development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed …
Ingenol mebutate: a new option for actinic keratosis treatment.
J Gras - Drugs of Today (Barcelona, Spain: 1998), 2013 - europepmc.org
Actinic keratosis, one of the most common dermatological pathologies manifests as ultraviolet-or
sun-induced macules, papules or plaques, and is considered a biomarker for the risk of …
sun-induced macules, papules or plaques, and is considered a biomarker for the risk of …
Pharmacological characterization of abediterol, a novel inhaled β2-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical …
…, M Vinals, I Ramos, A Gavalda, J De Alba, J Gras… - … of Pharmacology and …, 2012 - ASPET
Abediterol is a novel potent, long-acting inhaled β 2 -adrenoceptor agonist in development
for the treatment of asthma and chronic obstructive pulmonary disease. Abediterol shows …
for the treatment of asthma and chronic obstructive pulmonary disease. Abediterol shows …
Almotriptan, a new anti‐migraine agent: A review
J Gras, J Llenas, JM Jansat, J Jįuregui… - CNS drug …, 2002 - Wiley Online Library
Almotriptan is a new anti‐migraine agent with nanomolar affinity for human 5‐HT 1B , 5‐HT
1D , and 5‐HT 1F receptors, weak affinity for 5‐HT 1A and 5‐HT 7 receptors and no …
1D , and 5‐HT 1F receptors, weak affinity for 5‐HT 1A and 5‐HT 7 receptors and no …
Mirabegron for the treatment of overactive bladder.
J Gras - Drugs of Today (Barcelona, Spain: 1998), 2012 - europepmc.org
Overactive bladder (OAB) syndrome is defined as urinary urgency, usually accompanied by
frequency and nocturia, with or without urge urinary incontinence, in the absence of urinary …
frequency and nocturia, with or without urge urinary incontinence, in the absence of urinary …
Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
J Gras - Drugs of Today (Barcelona, Spain: 1998), 2013 - europepmc.org
After AIDS, tuberculosis (TB) is the leading killer worldwide due to a single infectious agent.
Recently, drug-resistant strains of Mycobacterium tuberculosis elicited even more severe …
Recently, drug-resistant strains of Mycobacterium tuberculosis elicited even more severe …
Synthesis and Structure−Activity Relationships of Novel Histamine H1 Antagonists: Indolylpiperidinyl Benzoic Acid Derivatives
…, M Aparici, E Calaf, J Prieto, J Gras… - Journal of medicinal …, 2004 - ACS Publications
A series of indolylpiperidinyl derivatives were prepared and evaluated for their activity as
histamine H 1 antagonists. Structure−activity relationship studies were directed toward …
histamine H 1 antagonists. Structure−activity relationship studies were directed toward …
Comparative antiallergic effects of second-generation H1-antihistamines ebastine, cetirizine and loratadine in preclinical models
J Llupią, J Gras, J Llenas - Arzneimittelforschung, 2003 - thieme-connect.com
Ebastine (CAS 90729-43-4), cetirizine (CAS 83881-51-0) and loratadine (CAS 79794-75-5)
are second generation H 1 -antihistamines of proven efficacy for treating allergy. Recent …
are second generation H 1 -antihistamines of proven efficacy for treating allergy. Recent …
Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile
A Gavaldą, J Gras, J Llupią, J Aubets, J Beleta… - Life sciences, 2012 - Elsevier
AIMS: Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist currently in
registration phase for the treatment of chronic obstructive pulmonary disease. Since urinary …
registration phase for the treatment of chronic obstructive pulmonary disease. Since urinary …
Functional profile of almotriptan in animal models predictive of antimigraine activity
J Gras, J Bou, J Llenas, AG Fernįndez… - European journal of …, 2000 - Elsevier
Almotriptan is a new 5-HT 1B/1D receptor agonist whose clinical efficacy for the treatment of
migraine attacks has been demonstrated in Phase III clinical trials. We now compare the …
migraine attacks has been demonstrated in Phase III clinical trials. We now compare the …